Canon Medical Research to develop AI prototype

Published: 14 August 2018

Canon Medical Research Europe has been awarded £140,000 to develop a prototype to improve assessment for one of the most difficult cancers to manage, Malignant Pleural Mesothelioma (MPM).

The Cancer Innovation Challenge aims to inspire novel data and technology innovations to help Scotland become a world leader in cancer care. Funded by Scottish Government through the Scottish Funding Council and delivered by three Scottish innovation centres led by The Data Lab, this Phase II funding focuses on identifying innovative ways to improve cancer treatment and outcomes using data science.

This research, if successful, will bring us closer to vital advances in cancer treatment through data science...

Ivan McKee MSP, Minister for Trade, Investment and Innovation, The Scottish Government

 

Bureau Plus virtual accounts Working with renowned mesothelioma physician and researcher, Dr Kevin Blyth of NHS Greater Glasgow and Clyde, Canon Medical is seeking to show that AI can be an effective tool in the fight against this particularly challenging cancer.

If successful, the company hopes to start development on an AI tool that will recognise, assess and measure cancer tumours, while contributing to the growing body of evidence for how AI can help medical advancement across the world. Scotland has one of the highest incidence rates of mesothelioma, sometimes known as ‘asbestos cancer’, in the world. Unlike most types of tumour, which are roughly spherical in shape, mesothelioma grows in a skin-like manner around the lung.

This makes measuring its size much more time-consuming and error-prone than for other cancers. Without a reliable measurement it is very difficult to gauge how well a treatment is working, or to choose the most effective treatment for each patient.

This project will develop AI technology that rapidly and accurately measures the size of the mesothelioma tumour, which could form an important component of a precision medicine system for treating patients with the disease...

Full story via SBNN News

Share

Latest tweets

follow us @InvestEdinburgh